JETRO Opens Japan Entry Acceleration Program 2026 for Regenerative Medicine Companies
JETRO has opened applications for JEAP 2026, a Japan-entry acceleration program for overseas regenerative-medicine companies seeking Japanese partners.
Insights
JETRO has opened applications for JEAP 2026, a Japan-entry acceleration program for overseas regenerative-medicine companies seeking Japanese partners.
JFTC published compliance reports submitted by designated smartphone software operators and opened channels for related information and violation reports.
JETRO is promoting Japanese products in Ukraine through Wine Bureau and its Goodwine retail and e-commerce channels in Kyiv.
JETRO's new Human Rights Policy is not just institutional language. It signals that responsible supply chains, supplier screening, and trust are becoming part of Japan's business infrastructure.
Japan remains attractive to foreign companies, but the entry question is changing. The companies that perform well are not simply chasing growth. They are reducing uncertainty before they commit.
apan already has strong inbound tourism demand. The next opportunity is helping the tourism industry operate better under labor shortages, regional pressure, digital gaps, and rising visitor expectations.
Japan does not reject new technology by default. But Japanese buyers need to understand who is responsible when something fails, who supports the system, and how risk is controlled.
Japan is open to foreign companies, capital, and technology. But in a high-risk world, Japan is not only asking what you sell. It is asking whether you can be trusted as a partner.
Japan's FDI push and stronger screening are not contradictory. They show that Japan wants foreign capital, technology, and ideas, but not blind investment.
Japan is still open to foreign companies, but entry is becoming more selective. The companies that prepare for partnerships, not just promotion, will have a stronger chance.